Search results for "Low pH"

showing 4 items of 14 documents

White cord syndrome after non-contiguous double-level anterior cervical decompression and fusion (ACDF): A “no reflow phenomenon”?

2017

Abstract Study design Case report and review of literature. Objective To report a rare complication of anterior cervical decompression and fusion (ACDF) in a patient with severe cervical cord compression and review of relevant literature. Introduction The white cord syndrome is a very rare condition characterized by an ischemic-edematous lesion of the spinal cord following a surgical procedure, lacking intra o perioperative surgical or anesthesiological complications. Case report A 64-years old male affected by a severe cervical stenosis at multiple levels, with voluminous C3–C4 and C5–C6 disc herniations associated to T2-hyperintense myelomalacic area at C3–C4 level was admitted to our Uni…

medicine.medical_specialtyCordmedicine.medical_treatmentlcsh:Surgerylcsh:RC346-42903 medical and health sciences0302 clinical medicineDiscectomymedicinelcsh:Neurology. Diseases of the nervous systemSettore MED/27 - Neurochirurgiabusiness.industryCerebral infarctionPerioperativeCervical cord compressionlcsh:RD1-811medicine.diseaseSpinal cordspinal cord injurySurgerymedicine.anatomical_structure030220 oncology & carcinogenesisNo reflow phenomenonSurgeryNeurology (clinical)Neurosurgerybusiness030217 neurology & neurosurgeryInterdisciplinary Neurosurgery
researchProduct

Coronary microvascular dysfunction

2020

Patients with coronary microvascular dysfunction (CMVD) represent a widespread population and despite the good prognosis, many of them have a poor quality of life with strong limitations in their daily activities because of the angina symptoms. This article summarizes the most frequent clinical presentation pictures like stable and unstable microvascular angina. Main risk factors are discussed, followed by the latest updates on the subject about different pathogenic hypotheses, diagnosis and treatment. Not very well understood microvascular alterations, like slow flow phenomenon and no reflow are discussed and both prognosis and the impact of the disease in the quality of life are analyzed.

medicine.medical_specialtyMyocardial ischemiaMyocardial ischemiaPopulationDisease030204 cardiovascular system & hematologyPoor quality03 medical and health sciences0302 clinical medicineMicrovascular anginaRisk FactorsCoronary CirculationInternal medicineHumansMedicine030212 general & internal medicineAngina symptomseducationeducation.field_of_studybusiness.industryMicrovascular anginaSlow-Flow PhenomenonPrognosisCoronary VesselsHearth failureQuality of LifeCardiologyNo-Reflow PhenomenonCardiology and Cardiovascular Medicinebusiness
researchProduct

Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rab…

1996

Objective: The complement system has been suggested to play a role in reperfusion injury which may result from an enhanced destruction of myocardial tissue or from an impairment of reflow. We investigated the influence of the C5b-9 complement complex on infarct size, reflow and arrhythmogenesis. Methods: Twenty-eight C6-competent rabbits and 18 rabbits with congenital C6 deficiency were subjected to either 30 min or 2 h of coronary artery occlusion followed by reperfusion. C6 deficiency was confirmed by the complement titration test and immunohistology. The triphenyl tetrazolium chloride method was used to delineate infarct size. Reflow into infarcted areas was evaluated histologically afte…

medicine.medical_specialtyTime FactorsPhysiologyMyocardial InfarctionIschemiaInfarctionMyocardial Reperfusion InjuryComplement Membrane Attack ComplexElectrocardiographyReperfusion therapyPhysiology (medical)Internal medicinemedicineAnimalscardiovascular diseasesComplement Activationbusiness.industryArrhythmias Cardiacmedicine.diseaseImmunohistochemistryComplement C6Complement systemRegional Blood FlowCoronary occlusionNo reflow phenomenoncardiovascular systemCardiologyRabbitsCardiology and Cardiovascular MedicineComplement membrane attack complexbusinessReperfusion injuryCardiovascular Research
researchProduct

Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability …

2012

Background Although significant efforts have been made to improve ST-segment elevation myocardial infarction (STEMI) outcomes by reducing symptom-onset-to-reperfusion times, strategies to decrease the clinical impact of ischemic reperfusion injury have demonstrated limited success. Bendavia, an intravenously administered mitochondrial targeting peptide, has been shown to reduce myocardial infarct size and attenuate coronary no-reflow in experimental modelswhen given before reperfusion. Design The EMBRACE STEMI study is a phase 2a, randomized, double-blind, placebo-controlled trial enrolling 300 patients with a first-time anterior STEMI and an occluded proximal or mid–left anterior descendin…

medicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionPlacebo-controlled studyMyocardial Reperfusion InjuryPlaceboClinical Trials Phase II as TopicInternal medicinemedicineClinical endpointHumansInfusions Intra-ArterialST segmentcardiovascular diseasesMyocardial infarctionRandomized Controlled Trials as Topicbusiness.industryPatient SelectionPercutaneous coronary interventionmedicine.diseaseResearch DesignConventional PCICardiologyNo-Reflow PhenomenonStentsCardiology and Cardiovascular MedicinebusinessOligopeptidesReperfusion injuryAmerican Heart Journal
researchProduct